Cargando…

InforMing the PAthway of COPD Treatment (IMPACT) trial: fibrinogen levels predict risk of moderate or severe exacerbations

BACKGROUND: Fibrinogen is the first qualified prognostic/predictive biomarker for exacerbations in patients with chronic obstructive pulmonary disease (COPD). The IMPACT trial investigated fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy versus FF/VI and UMEC/VI in patients wi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Singh, Dave, Criner, Gerard J., Dransfield, Mark T., Halpin, David M. G., Han, MeiLan K., Lange, Peter, Lettis, Sally, Lipson, David A., Mannino, David, Martin, Neil, Martinez, Fernando J., Miller, Bruce E., Wise, Robert, Zhu, Chang-Qing, Lomas, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8080358/ https://www.ncbi.nlm.nih.gov/pubmed/33910578 http://dx.doi.org/10.1186/s12931-021-01706-y

Ejemplares similares

Prognostic value of clinically important deterioration in COPD: IMPACT trial analysis
por: Han, MeiLan K., et al.
Publicado: (2021)

The Effect of Inhaled Corticosteroid Withdrawal and Baseline Inhaled Treatment on Exacerbations in the IMPACT Study. A Randomized, Double-Blind, Multicenter Clinical Trial
por: Han, MeiLan K., et al.
Publicado: (2020)

The effect of exacerbation history on outcomes in the IMPACT trial
por: Halpin, David M.G., et al.
Publicado: (2020)

Single-Inhaler Triple Therapy and Health-Related Quality of Life in COPD: The IMPACT Study
por: Tabberer, Maggie, et al.
Publicado: (2020)

Risk of Exacerbation and Pneumonia with Single-Inhaler Triple versus Dual Therapy in IMPACT
por: Dransfield, Mark T., et al.
Publicado: (2021)

Triple Versus Dual Combination Therapy in Chronic Obstructive Pulmonary Disease in Asian Countries: Analysis of the IMPACT Trial
por: Halpin, David M. G., et al.
Publicado: (2020)

Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial
por: Day, Nicola C., et al.
Publicado: (2020)

Single-inhaler triple therapy in symptomatic COPD patients: FULFIL subgroup analyses
por: Halpin, David M.G., et al.
Publicado: (2018)

Time‐Dependent Risk of Cardiovascular Events Following an Exacerbation in Patients With Chronic Obstructive Pulmonary Disease: Post Hoc Analysis From the IMPACT Trial
por: Dransfield, Mark T., et al.
Publicado: (2022)

Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease
por: Lipson, David A., et al.
Publicado: (2020)

Discordant diagnostic criteria for pneumonia in COPD trials: a review
por: Wise, Robert A., et al.
Publicado: (2021)

Cost-Effectiveness Of Once-Daily Single-Inhaler Triple Therapy In COPD: The IMPACT Trial
por: Ismaila, Afisi S, et al.
Publicado: (2019)

Measuring disease activity in COPD: is clinically important deterioration the answer?
por: Singh, Dave, et al.
Publicado: (2020)

Correction to: Measuring disease activity in COPD: is clinically important deterioration the answer?
por: Singh, Dave, et al.
Publicado: (2021)

Effect of chronic mucus hypersecretion on treatment responses to inhaled therapies in patients with chronic obstructive pulmonary disease: Post hoc analysis of the IMPACT trial
por: Thompson, Philip J., et al.
Publicado: (2022)

Single-Inhaler Triple Therapy in Patients with Advanced COPD: Bayesian Modeling of the Healthcare Resource Utilization Data and Associated Costs from the IMPACT Trial
por: Gabrio, Andrea, et al.
Publicado: (2022)

Python Scripts for Asset Management with Infor EAM
por: Matthes, Amanda Roxanna
Publicado: (2019)

G-InforBIO: integrated system for microbial genomics
por: Tanaka, Naoto, et al.
Publicado: (2006)

Frequency of Exacerbations in COPD: An Analysis of the SPIROMICS Cohort
por: Han, MeiLan K., et al.
Publicado: (2017)

Exacerbation frequency and course of COPD
por: Halpin, David MG, et al.
Publicado: (2012)

Fibrinogen, chronic obstructive pulmonary disease (COPD) and outcomes in two United States cohorts
por: Valvi, Deepa, et al.
Publicado: (2012)

From GOLD 0 to Pre-COPD
por: Han, MeiLan K., et al.
Publicado: (2021)

Blood fibrinogen as a biomarker of chronic obstructive pulmonary disease
por: Duvoix, Annelyse, et al.
Publicado: (2013)

StreptomycesInforSys: A web-enabled information repository
por: Jain, Chakresh Kumar, et al.
Publicado: (2012)

Blood eosinophils: a biomarker of COPD exacerbation reduction with inhaled corticosteroids
por: Siddiqui, Salman H, et al.
Publicado: (2018)

Differential DNA methylation marks and gene comethylation of COPD in African-Americans with COPD exacerbations
por: Busch, Robert, et al.
Publicado: (2016)

Impact and prevention of severe exacerbations of COPD: a review of the evidence
por: Halpin, David MG, et al.
Publicado: (2017)

Novel Respiratory Disability Score Predicts COPD Exacerbations and Mortality in the SPIROMICS Cohort
por: Cooper, Christopher B, et al.
Publicado: (2020)

“Reading the Mind in the Eyes” in Autistic Adults is Modulated by Valence and Difficulty: An InFoR Study
por: Baltazar, Matias, et al.
Publicado: (2020)

β-Blockers for the prevention of acute exacerbations of chronic obstructive pulmonary disease (βLOCK COPD): a randomised controlled study protocol
por: Bhatt, Surya P, et al.
Publicado: (2016)

Identification of discriminative characteristics for clusters from biologic data with InforBIO software
por: Tanaka, Naoto, et al.
Publicado: (2007)

Acute exacerbations of COPD versus IPF in patients with combined pulmonary fibrosis and emphysema
por: Zantah, Massa, et al.
Publicado: (2020)

Preventing clinically important deterioration with single-inhaler triple therapy in COPD
por: Naya, Ian, et al.
Publicado: (2018)

InforMD: a new initiative to raise public awareness about breast density
por: Hugo, Honor J, et al.
Publicado: (2018)

Azithromycin and risk of COPD exacerbations in patients with and without Helicobacter pylori
por: Ra, Seung Won, et al.
Publicado: (2017)

Effect of beta-blockers on exacerbation rate and lung function in chronic obstructive pulmonary disease (COPD)
por: Duffy, Sean, et al.
Publicado: (2017)

Risk factors for COPD exacerbations in inhaled medication users: the COPDGene study biannual longitudinal follow-up prospective cohort
por: Busch, Robert, et al.
Publicado: (2016)

CT measurements of central pulmonary vasculature as predictors of severe exacerbation in COPD
por: Rho, Ji Young, et al.
Publicado: (2018)

Lower serum IgA is associated with COPD exacerbation risk in SPIROMICS
por: Putcha, Nirupama, et al.
Publicado: (2018)

Impact of bronchiectasis on the frequency and severity of respiratory exacerbations in COPD
por: Labaki, Wassim W, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_nkrn3t175k1ka7heinvin515lm